Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.56 |
| ▸ | SRC | P12931 | 5/20 | 0.56 |
| ▸ | CSK | P41240 | 1/20 | 0.53 |
| ▸ | TEK | Q02763 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 14/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.50 |
| ▸ | FLT1 | P17948 | 7/20 | 0.50 |
| ▸ | FLT4 | P35916 | 7/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445304 | 0.86 | KDR (0.66) | KDRSRCCSKTEKEGFR | |
| SCHEMBL6451233 | 0.85 | KDR (0.44) | KDRSRCCSKTEKEGFR | |
| SCHEMBL6448196 | 0.85 | KDR (0.74) | KDRSRCCSKTEKEGFR | |
| SCHEMBL6445791 | 0.79 | KDR (0.66) | KDRSRCCSKTEKEGFR | |
| SCHEMBL6445013 | 0.79 | KDR (0.80) | KDRSRCCSKTEKEGFR | |
| SCHEMBL3680310 | 0.78 | KDR (0.87) | KDRSRCCSKTEKEGFR | |
| SCHEMBL7252484 | 0.76 | KDR (0.66) | KDRSRCCSKTEKEGFR | |
| SCHEMBL6445629 | 0.74 | KDR (0.67) | KDRSRCFLT1ERBB2EPHA2 | |
| SCHEMBL6445635 | 0.74 | KDR (0.67) | KDRSRCFLT1ERBB2EPHA2 | |
| SCHEMBL6444241 | 0.74 | KDR (0.59) | KDRSRCCSKTEKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002030924-A9 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |